$6.25
▲ +0.3% Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wedbush Adjusts Zura Bio Price Target to $22 From $15, Maintains Outperform Rating
Overview
52-week range
$1.88
$7.44
79% of range
Avg surprise (last 3)
-10.2%
Avg reaction (last 2)
-2.4%
50% positive
Latest IV / EM
512%
EM ±80.0% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.21 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.22 | $-0.17 | -29.4% | -15.8% | -7.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.17 | $-0.19 | +10.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.19 | $-0.17 | -11.8% | — | +2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.26 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.17 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.18 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.31 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-2.76 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-29M | $-25M | — | $-20M | $-18M | $-19M | — | $-19M |
| Net income | $-26M | $-24M | — | $-18M | $-16M | $-17M | — | $-21M |
| EPS (diluted) | $-0.21 | $-0.22 | — | $-0.21 | $-0.17 | $-0.19 | — | $-0.26 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $205M | $226M | $109M | $139M | $154M | $171M | $176M | $188M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $210M | $227M | $112M | $142M | $157M | $172M | $179M | $189M |
| Total assets | $213M | $229M | $114M | $144M | $158M | $172M | $180M | $189M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $16M | $12M | $12M | $25M | $19M | $21M | $20M | $18M |
| Total equity | $197M | $217M | $102M | $108M | $127M | $140M | $147M | $154M |